Hisamitsu Pharmaceutical Co., Inc. (TYO:4530)

Japan flag Japan · Delayed Price · Currency is JPY
4,165.00
-20.00 (-0.48%)
Sep 26, 2025, 3:30 PM JST
-0.48%
Market Cap296.25B
Revenue (ttm)154.86B
Net Income (ttm)19.53B
Shares Out71.13M
EPS (ttm)266.77
PE Ratio15.61
Forward PE15.76
Dividend90.00 (2.16%)
Ex-Dividend DateAug 28, 2025
Volume221,000
Average Volume176,480
Open4,167.00
Previous Close4,185.00
Day's Range4,148.00 - 4,204.00
52-Week Range3,783.00 - 4,735.00
Beta0.39
RSI39.64
Earnings DateOct 9, 2025

About TYO:4530

Hisamitsu Pharmaceutical Co., Inc. manufactures and sells pharmaceuticals in Japan. The company provides external pain-relieving drugs under the SALONPAS, NOBINOBI, SALONSIP, AIR, SALONPAS, and FEITAS; BUTENALOCK, a remedy for athlete′s foot; and ALLEGRA FX, a sinus medication for allergies. It also manufactures and sells quasi-drugs and cosmetics; MOHRUS TAPE and MOHRUS PAP XR, a transdermal analgesic anti-inflammatory drug; and patches for female hormone, asthma, and overactive bladders. The company exports its products to Asia, the United St... [Read more]

Sector Healthcare
Founded 1847
Employees 2,799
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4530
Full Company Profile

Financial Performance

In 2024, TYO:4530's revenue was 156.01 billion, an increase of 10.09% compared to the previous year's 141.71 billion. Earnings were 21.76 billion, an increase of 55.76%.

Financial Statements

News

There is no news available yet.